Related Experiment Video
Updated: Jan 1, 2026

Modified Yeast-Two-Hybrid System to Identify Proteins Interacting with the Growth Factor Progranulin
Published on: January 17, 2012
Progranulin deficiency leads to enhanced age-related cardiac hypertrophy through complement C1q-induced β-catenin
Yinghong Zhu1, Tohru Ohama2, Ryota Kawase3
1Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
Insights
Progranulin (PGRN) deficiency accelerates cardiac aging and hypertrophy in mice. This occurs through complement C1q (C1q) activating beta-catenin, leading to heart dysfunction. PGRN may be a therapeutic target for heart aging.
Area of Science:
- Cardiovascular biology
- Aging research
- Molecular cardiology
Background:
- Age-related cardiac hypertrophy and heart failure pose significant health challenges.
- Progranulin (PGRN) deficiency is linked to accelerated brain aging.
- The impact of PGRN deficiency on cardiac aging remains largely unexplored.
Purpose of the Study:
- To investigate the effects of PGRN deficiency on cardiac aging, specifically left ventricular hypertrophy.
- To elucidate the molecular mechanisms underlying PGRN deficiency-induced cardiac aging.
Main Methods:
- Longitudinal echocardiography in wild-type (WT) and PGRN-knockout (KO) mice from 3 to 18 months.
- Morphological analysis of heart weight, cardiomyocyte size, lipofuscin accumulation, and senescence markers.
- Assessment of complement C1q (C1q) and beta-catenin protein expression.
- In vitro studies using PGRN-deficient cardiomyocytes treated with C1q and/or C1q inhibitors.
Main Results:
- PGRN KO mice exhibited age-dependent cardiac hypertrophy and dysfunction by 18 months.
- Increased heart weight, cardiomyocyte size, lipofuscin, and senescence markers were observed in aged PGRN KO mice.
- Enhanced C1q and activated beta-catenin were found in aged PGRN KO hearts; C1q induced hypertrophy via beta-catenin, which was blocked by C1q inhibition. C1 inhibitor treatment ameliorated cardiac issues in KO mice.
Conclusions:
- PGRN deficiency exacerbates age-related cardiac hypertrophy and dysfunction.
- The mechanism involves C1q-mediated activation of beta-catenin signaling.
- PGRN represents a potential therapeutic target for preventing cardiac hypertrophy and dysfunction in aging populations.
Aims:
Age-related cardiac hypertrophy and subsequent heart failure are predicted to become increasingly serious problems in aging populations. Progranulin (PGRN) deficiency is known to be associated with accelerated aging in the brain. We aimed to evaluate the effects of PGRN deficiency on cardiac aging, including left ventricular hypertrophy.
Methods And Results:
Echocardiography was performed on wild-type (WT) and PGRN-knockout (KO) mice every 3 months from 3 to 18 months of age. Compared to that of WT mice, PGRN KO mice exhibited age-dependent cardiac hypertrophy and cardiac dysfunction at 18 months. Morphological analyses showed that the heart weight to tibia length ratio and cross-sectional area of cardiomyocytes at 18 months were significantly increased in PGRN KO mice relative to those in WT mice. Furthermore, accumulation of lipofuscin and increases in senescence markers were observed in the hearts of PGRN KO mice, suggesting that PGRN deficiency led to enhanced aging of the heart. Enhanced complement C1q (C1q) and activated β-catenin protein expression levels were also observed in the hearts of aged PGRN KO mice. Treatment of PGRN-deficient cardiomyocytes with C1q caused β-catenin activation and cardiac hypertrophy. Blocking C1q-induced β-catenin activation in PGRN-depleted cardiomyocytes attenuated hypertrophic changes. Finally, we showed that C1 inhibitor treatment reduced cardiac hypertrophy and dysfunction in old KO mice, possibly by reducing β-catenin activation. These results suggest that C1q is a crucial regulator of cardiac hypertrophy induced by PGRN ablation.
Conclusion:
The present study demonstrates that PGRN deficiency enhances age-related cardiac hypertrophy via C1q-induced β-catenin activation. PGRN is a potential therapeutic target to prevent cardiac hypertrophy and dysfunction.
More Related Videos
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Pathophysiology of Heart Failure
Catenins
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the...
Myocarditis I: Introduction
Heart Failure II: Pathophysiology
TGF - β Signaling Pathway

